Literature DB >> 25390744

Rapid evolution of combination therapy in melanoma.

Brendan D Curti1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25390744     DOI: 10.1056/NEJMe1411158

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness.

Authors:  Zixi Zhang; Shaojun Zhu; Yang Yang; Xianjie Ma; Shuzhong Guo
Journal:  Tumour Biol       Date:  2015-06-04

2.  A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.

Authors:  Jia-Hua Feng; Kyoko Nakagawa-Goto; Kuo-Hsiung Lee; Lie-Fen Shyur
Journal:  Mol Cancer Ther       Date:  2016-04-05       Impact factor: 6.261

3.  Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines.

Authors:  O A Ahmed; C Kelly
Journal:  J Laryngol Otol       Date:  2016-05       Impact factor: 1.469

4.  Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.

Authors:  Imran H Chowdhury; Eric Ojerholm; Matthew T McMillan; Denise Miller; James D Kolker; Goldie Kurtz; Jay F Dorsey; Suneel N Nagda; Geoffrey A Geiger; Steven Brem; Donald M O'Rourke; Eric L Zager; Tara Gangadhar; Lynn Schuchter; John Y K Lee; Michelle Alonso-Basanta
Journal:  Radiat Oncol       Date:  2015-12-01       Impact factor: 3.481

Review 5.  Tailoring the Treatment of Melanoma: Implications for Personalized Medicine.

Authors:  Linna Duan; Eric M Mukherjee; Deepak Narayan
Journal:  Yale J Biol Med       Date:  2015-11-24

Review 6.  MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy.

Authors:  Khiem A Tran; Michelle Y Cheng; Anupam Mitra; Hiromi Ogawa; Vivian Y Shi; Laura P Olney; April M Kloxin; Emanual Maverakis
Journal:  Drug Des Devel Ther       Date:  2015-12-21       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.